TW200932756A - External skin treatment composition comprising silybin glycosides - Google Patents
External skin treatment composition comprising silybin glycosides Download PDFInfo
- Publication number
- TW200932756A TW200932756A TW098100842A TW98100842A TW200932756A TW 200932756 A TW200932756 A TW 200932756A TW 098100842 A TW098100842 A TW 098100842A TW 98100842 A TW98100842 A TW 98100842A TW 200932756 A TW200932756 A TW 200932756A
- Authority
- TW
- Taiwan
- Prior art keywords
- glycoside
- water
- silybin
- formula
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
200932756 六、發明說明: 【發明所屬之技術領域】 本發明係關於一種皮膚外用組合物。 【先前技術】 已知含有以水飛勤負為主要成分的水飛莉素對防止皮膚老化 有效,在治療紅斑、燙傷、皮膚或粘膜的營養不良狀態、皮膚炎200932756 VI. Description of the Invention: [Technical Field to Be Invented] The present invention relates to a composition for external use on skin. [Prior Art] It is known that difloxacin containing water as a main component is effective in preventing skin aging, in the treatment of erythema, burns, dystrophic state of skin or mucous membranes, dermatitis
等時可有效促進治癒’且可有效保護皮膚不受外部環境的刺激(放 射線、風、太陽等)(參照專利文獻丨:曰本特開平M〇〇132號 公報),此外,已知水飛莉賓之表皮角質細胞的分化抑制效果(參 照專利文獻2 :日本特開2_-_7號公報)、含有以水飛莉賓為 主要成分的水飛S素之I型膠原蛋白產生促進作用(參照專利文 獻 3 : W02004/85429 號公報)。 另-方面’因為水飛難幾乎不溶於水、油中,所以存在菊 於在水系組合财配合的_,已公開有:使水賴素分散_ 料的技術(參照專利文獻4 :日本特開齡聰號公報),顧 使水飛15素職_旨複合物,有觀其生物體舰性的技術㈢ =利文獻1:日本制平卜1G_號公報),形成微乳劑組合物 =生物彻度賴術(參照專利讀5 :日本特表細_5酬 ’使脚〈糊精衍生物製造水飛_ _的_參照 專利文獻6:日本·平3售_號公報)。 P使使用k些技*,有時也並不能完全抑制水飛莉賓 200932756 的析出,而且即使可抑制水_t的析出,在處方餅上也存在 制約。 已知水飛莉賓的«萄糖配糖體、半乳糖配糖體、乳糖配糖體、 麥芽糖配糖體具有抗氧化作用,與水賴賓概水雜優異(參 1 * Kosina P. et al., Phytother. Res. 16, S33-S39 (2002))。但是亚不清楚含有水飛莉賓配糖體的皮膚外用組合 物、水飛莉賓配糖體的皺紋形成抑制效果、表皮角質細胞分化抑 制效果、I型膠原蛋白產生促進效果。 0 【專利文獻1】曰本特開平1-100132號公報 【專利文獻2】日本特開2004-91397號公報 【專利文獻3】W02004/85429號公報 ’ 【專利文獻4】日本特開2002-34505號公報 - 【專利文獻5】曰本特表2003-503441號公報 【專利文獻6】日本特開平3-206090號公報 【非專利文獻 1】Kosina P· et al·,Phytother. Res. 16, S33-S39 ❹ (2002) 【發明内容】 本發明之課題是開發以水飛薊賓配糖體為有效成分的皮膚外 用組合物等。 本發明者通過使用水飛薊賓配糖體完成本發明。 4 200932756 亦即,本發明之主要構成如下所述: (1) 一種皮膚外用組合物,其含有水飛薊賓配糖體。 (2) 如(1)所述之皮膚外用組合物,其特徵在於,水飛薊 賓配糖體為式(1)的水飛薊賓乳配糖體或式(2)的水飛薊賓參 芽配糖體。Isochronization can effectively promote healing and can effectively protect the skin from external environment (radiation, wind, sun, etc.) (refer to the patent document 曰: 曰本特开平M〇〇132号), in addition, it is known that water can be used. The effect of inhibiting the differentiation of the epidermal keratinocytes of Libin (refer to Japanese Patent Laid-Open No. Hei 2_-_7), and the promotion of the production of type I collagen containing S. sinensis as a main component (see Patent Document 3: WO2004/85429). In addition, it is a technique for dispersing water lysine (see Patent Document 4: JP-A-Japan), because it is hardly soluble in water and oil. "Innocence Bulletin", Gu Shui Shuifei 15 Sustained _ _ complex, there is a technology to view its biological ship (3) = Li Literature 1: Japan made Ping Bu 1G_ bulletin), the formation of microemulsion composition = biological In the case of the singularity of the singularity of the singularity of the singularity of the singularity of the singularity of the product. P makes use of some techniques*, and sometimes does not completely inhibit the precipitation of the water fly Libin 200932756, and even if the precipitation of water _t can be suppressed, there is a restriction on the prescription cake. It is known that the sugar glycoside, galactose glycoside, lactose glycoside, and maltose glycoside have antioxidative effects, and are excellent in water and water. (Ref. 1 * Kosina P. et al. , Phytother. Res. 16, S33-S39 (2002)). However, it is not clear that the skin external composition containing the watery lycopene glycoside, the wrinkle formation inhibitory effect of the watery lycopene glycoside, the epidermal keratin cell differentiation inhibiting effect, and the type I collagen production promoting effect. [Patent Document 1] Japanese Laid-Open Patent Publication No. 2004-91397 (Patent Document 3) WO2004/85429 (Patent Document 4) Japanese Patent Laid-Open No. 2002-34505 [Patent Document 5] 曰本本表-2003-503441 [Patent Document 6] JP-A-3-206090 [Non-Patent Document 1] Kosina P. et al., Phytother. Res. 16, S33 - S39 ❹ (2002) [Explanation] An object of the present invention is to develop a skin external composition containing a silibinose glycoside as an active ingredient. The present inventors completed the present invention by using a silibinin glycoside. 4 200932756 That is, the main constitution of the present invention is as follows: (1) A skin external composition containing a silybin glycoside. (2) The composition for external use on skin according to (1), wherein the silybin glycoside is a silibinin glycoside of the formula (1) or a silibinin of the formula (2) The buds are glycosides.
OHOH
式(2) (3) —種皺紋形成抑制劑,其中,以水飛薊賓配糖體為有效 成分。 5 200932756 (4) 一種表皮角質細胞分化抑制劑,其中,以水飛薊賓配糖 體為有效成分。 (5) —種I型膠原蛋白產生促進劑,其中,以水飛薊賓配糖 體為有效成分。 _ (6) —種日曬所致的皮膚粗糙改善劑,其中,以水飛薊賓配 糖體為有效成分。 (7) 如(3)〜(6)中任一項所述之製劑,其特徵在於,水 飛薊賓配糖體為式(1)的水飛薊賓乳配糖體或式(2)的水飛薊 ® 賓麥芽配糖體。Formula (2) (3) An inhibitor of wrinkle formation in which a silybin glycoside is used as an active ingredient. 5 200932756 (4) An epidermal keratinocyte differentiation inhibitor in which a silibinin glycoside is used as an active ingredient. (5) A type I collagen production promoter, wherein a silibinin glycoside is used as an active ingredient. _ (6) A skin roughness improving agent for sun exposure, in which a silybin glycoside is used as an active ingredient. (7) The preparation according to any one of (3) to (6), wherein the silybin glycoside is a silybin milk glycoside of the formula (1) or a formula (2) This milk thistle® bin malt glyceose.
式(1) 6 200932756Formula (1) 6 200932756
OHOH
式(2) ❹Formula (2) ❹
(8)如(2)所述之皮膚外用組合物或(7)所述之製劑,其 特徵在於,以水為溶劑,含有水飛薊賓配糖體〇.〇〇〇8〜5 〇重量 %。 . 本發明之效果如下: 1.通過使麟解性高的水飛15賓配糖體,可提供使水飛莉賓 的作用機理提高的皮膚外驗合物、皺紋形成抑制劑、表皮角質 細胞分化抑侧、老化防止时膚外用組合物、丨型膠原蛋白產 生促進劑、日曬所致的皮膚_改善劑。_是水溶性增高,安 全性、低刺激性提高,使用範圍擴大。 2·特別是作為水飛薊賓配糖體’化學式〔n 八表不的水飛薊賓 乳配糖體或化學式(2)表示的水飛薊賓麥芽配糖體有效。 3·本發明使用的水飛薊賓配糖體,其水溶性高,可作為水溶 液型的劑型利用。可製成化妝水、乳液、乳霜、面膜等皮膚外用 组合物’化⑽絲乳、化妝用m練或乳霜狀的2底等 7 200932756 化妝用皮膚外用组合物,護手霜、護腿霜、身體用乳液等身體用 皮膚外用组合物,入浴劑等。 4.本發明使用的水飛薊賓配糖體,可以在水中溶解〇. 〇〇〇8〜 5. 0重里%。即使是乳液等,也可在水性部分中大量配合。一 【實施方式】(8) The composition for external use on skin according to (2), or the preparation according to (7), which comprises water as a solvent and contains a silibinose glycoside 〇〇〇.〇〇〇8~5 〇 weight %. The effects of the present invention are as follows: 1. By providing a water-soluble 15 guest glycoside having high arsonability, it is possible to provide an exogenous skin composition, a wrinkle formation inhibitor, and an epidermal keratinocyte which enhance the mechanism of action of the water lycopene. The composition for external use, the composition for external use for preventing aging, the collagen-producing agent for sputum type, and the skin-improving agent for sun exposure. _ is an increase in water solubility, improved safety, low irritation, and expanded use. 2. In particular, it is effective as a silybin glycoside of the silybin formula, or a silybin maltoside glycoside represented by the chemical formula (2). 3. The silybin glycoside used in the present invention has high water solubility and can be used as a water-soluble type. It can be used as a skin external composition such as lotion, lotion, cream or mask. '10(s) silk milk, makeup m-training or cream-like 2 base, etc. 200932756 Cosmetic skin external composition, hand cream, leg warmer A body external composition such as a body lotion, a bathing agent, or the like. 4. The silybin glycoside used in the present invention can be dissolved in water. 〇〇〇8~5 0% by weight. Even in the case of an emulsion or the like, a large amount of the mixture can be blended in the aqueous portion. [Embodiment]
水飛莉賓(Si lybin; CAS No. 22888-70-6)是從菊科水飛蓟(学 名Silibum marianum Gaertn,别名大蓟、大翅蓟、乳蓟;CAS ❹ No. 84604-20-6)中萃取的黄酮木脂素的一種,從水飛蓟中萃取的 黄酮木脂素總稱為水飛薊素(Siiymarin ; cas No. 65666-07-1), 除水飛,薊賓之外,還含有水飛蓟寧(Silydianin ; CAS Να 29782-68-1)、水飛蓟亭(si lychristin; CAS No. 33889-69-9)、 異水飛蓟賓(Isosilybin ; CAS No. 7258卜71-6)等。 水飛威賓,可使用色譜法從水飛薊素中分離,此外也可通過 購買試劑而獲得。 Ο 水飛薊賓配糖體,可按照文獻(KrenV. etal.,j.Chem.Soc.,Silybin (CAS No. 22888-70-6) is from the genus Sylvestris sylvestris (scientific name Silibum marianum Gaertn, alias big cockroach, big-winged pheasant, chyle; CAS ❹ No. 84604-20-6 a kind of flavonol lignan extracted from the milk thistle, the flavonoid lignan extracted from the milk thistle is called silymarin (Casi. Cas No. 65666-07-1), in addition to water, and also contains water. Silydianin (CAS Να 29782-68-1), Sily lychristin (CAS No. 33889-69-9), Isosilybin (CAS No. 7258, 71-6) Wait. Shuifeiweibin can be separated from silymarin by chromatography, or it can be obtained by purchasing reagents. Ο Silibinin glycosides can be used according to the literature (KrenV. et al., j.Chem.Soc.,
Perkin Trans 1,2467-2474 ( 1997)),以路易 士酸為催化劑,通 過在水氣魚彳負上結合用乙酿基保護經基的糖,進行脫乙隨化而製 備。在該反應體系中,糖選擇性地與水飛莉素的伯醇的羥基形成 配糖鍵。 以路易士酸為催化劑,通過使水飛薊賓和全乙酿化乳糖反應 8 200932756 生成配糖鍵,脫乙醯化而獲得武(1)的水飛薊賓乳配糖體。Perkin Trans 1, 2467-2474 (1997)), using Lewis acid as a catalyst, is prepared by combining the sugar of the base with a water-based fish carp to protect the base sugar. In the reaction system, the sugar selectively forms a glycosyl bond with the hydroxyl group of the primary alcohol of the water. Using Lewis acid as a catalyst, by reacting silibinin and whole-bestinized lactose 8 200932756 A glycosidic bond is formed, which is deacetylated to obtain the silibinin milk glycoside of Wu (1).
以路易士酸為催化劑,通過使水飛薊賓和全乙醯化麥芽糖反 應生成配糖鍵,脫乙醯化,獲得式(2)的水飛薊賓麥芽配糖體。Using Lewis acid as a catalyst, a glycosidic bond is formed by reacting silibinin and total acetylated maltose to deacetylate to obtain a silibinin maltose glycoside of formula (2).
HOHO
式(2) ❹ 本發明使關水_㈣㈣,水溶性優異,水賴賓乳配 糖體、水飛射麥芽配糖體在水中可溶解約视。因此,在以往不 能配合水賴賓的化妝水類中,如果是水鋪f配糖體,就可配 合0 9 200932756 在本發_皮膚外賴合财,在不縣树日㈣效果的範 圍内,可含有油劑、表面活性劑、防腐劑、多树、乙醇、糖類、 金屬離子封翻、水雜高分子類高分子、增_、粉體成分、 紫外線吸收劑、紫外線遮斷劑、保濕劑、香料、pH調節劑等。此 外,也可含有維生素類、皮膚賦活劑、血流促進劑、常駐菌控^ 劑、活性氧清除劑、抗炎症劑、美白劑、殺菌劑等其他藥效成分、 生理活性成分。 本發明使⑽水飛15賓@嫌_水溶性優異,所以本發明中 水飛莉賓乳配糖體、水飛15賓麥芽配糖體在水$可溶解約观。因 此,在以往難於配合水鋪㈣化妝水類中,也可配合水飛葡寶 配糖體。 作為以本發明的水飛,15賓配糖體為有效成分_紋形成抑制 劑’可例舉錄水、魏、乳霜、_等敝改翻皮膚外用組 合物、敏紋改善用醫藥部外品、敏紋改善用醫藥等。即使是乳液, 也可在水性部分高濃度配合水飛薊賓配糖體。 以本發明的水_賓配㈣為有效成分的表皮肖質細胞分化 抑制劑’抑織皮角質細胞的分化,轉增殖,並獅、防止、 改善代謝更新的延緩’防止因增齡、紫外線照射所致的表皮扁平 化,具有使老化皮膚再钱作用,所以可作為老化防止用皮膚外 用組合物使用。 以本fx明的水1¾貞配糖體為有效成分的I ^膠原蛋白產生 200932756 促進劑’使皮膚的張力、雜提高,可期待獅、防止、改善級 紋、鬆弛的效果’所以可作為老化防朗皮膚外用組合物使用。 〔水飛薊賓乳配糖體的合成〕 根據Helferich的方法合成水飛莉賓乳配糖體。 _ 在氛氣存在下,使水_賓(3. Gg、6. 和辛乙醒基 ^乳糖(6·3g、9. 2mol)在1_的二氣甲炫-乙腈(1 :卜v/v)的 /谷劑中,與三氟化硼二甲基鱗複合物〇14ml、以咖⑷在室溫 ® y娜反應1M、時。反應結束後用冰冷卻的同時,加人飽和碳酸 氣鈉水溶液,用150ml二氣甲烧萃取處理2次’在無水硫酸納處 理後用蒸發器除去萃取溶劑。 使三乙胺-曱醇-水(1 ·· δ : υ在35。〇反應3〇小時,然後 用蒸發器除去溶劑。使用B0NDESIL_cl8(Varian)進行純化,獲得 水炖4負乳配糖體(1. 〇 g、收率2〇% )。獲得的水飛薊賓乳配糖 體用MS圖譜確認’檢測出[M+H]+ : 8〇7 5的質譜峰。 ® 〔水飛薊賓麥芽配糖體的合成〕 根據Helferich的方法合成水飛薊賓麥芽配糖體。 在氮氣存在下’使水飛薊賓(3. 0 g、6. 2inol)和辛-〇-乙酼 基-D-麥芽糖(β. 3g、9. 2mol)在180ml的二氯甲烷一乙腈(1 : 1、 v/v)的溶劑中,與三氟化硼二甲基醚複合物(1.14ml、12. 4mmol ) 在至溫下攪拌反應19小時。反應結束後用冰冷卻的同時,加入飽 和碳酸氫鈉水溶液,用150ml二氣曱烷萃取處理2次,在無水硫 200932756 酸納處理後㈣發ϋ除去萃取溶劑。 奸使乙胺—甲醇—水(1 :8: 〇在35。匸反應洲小時,然後 用除去溶劑。使帛_ESIL-C18(Varian)進行純化,獲得 氣’ ί賓麥㈣糖體(丨.Qg、收率2()% )。獲得的水飛财麥芽孤 糖體用MS圖譜確認,檢測出[Μ+ΗΓ : 807· 5的質譜峰。 〔實施例1〕 水浴性試驗 1·實驗方法 在1. 5ml试官中稱取適量水飛賓、水㈣賓乳配糖體、水 關賓麥芽配糖體(以下將水賴賓簡寫為SB、水細賓乳配糖· 體間寫為SBL、水飛莉賓麥芽配糖體簡寫為Μ),在其中加入純. 淨水’配成各種濃度’通過目視來判定外觀透明性、以及在室溫 下進行離心分離〇5_rpm、5min)時是否有沈崎出。而且$ 於SB目為水溶性極差,在燒杯中稱取少量,加入水用授摔器授❹ 拌约1小時’停止混合操作!小時後没有發現沈殿物的就判定為 溶解。 表1Formula (2) ❹ The present invention enables Guanshui _(4)(4) to be excellent in water solubility, and the water repellency and the water-spraying malt glycoside are soluble in water. Therefore, in the case of the lotion that cannot be used in the past, if it is a water shop, it can be used in conjunction with 0 9 200932756 in the scope of the effect of the county tree (4). Containing oil, surfactant, preservative, multi-tree, ethanol, sugar, metal ion sealing, water polymer, _, powder component, UV absorber, UV blocker, moisturizer, Spices, pH adjusters, etc. In addition, it may also contain other medicinal ingredients and physiologically active ingredients such as vitamins, skin activating agents, blood flow promoters, resident bacteria control agents, active oxygen scavengers, anti-inflammatory agents, whitening agents, and bactericides. The present invention makes (10) Shuifei 15 Bin@@ _ water-soluble excellent, so in the present invention, Shuifei Libin milk glycoside, Shuifei 15-bin malt glycoside can be dissolved in water. Therefore, in the past, it was difficult to match the water (4) lotion, and it was also possible to match the syrup. As the water-spraying agent of the present invention, the 15-glycoside-containing saccharide is an active ingredient-pattern formation inhibitor, and examples thereof include a composition for external use of water, Wei, cream, _, etc. Products, sensation improvement medicines, etc. Even in the case of emulsions, it is possible to mix the silybin glycoside at a high concentration in the aqueous portion. The differentiation of the epidermal dermal keratinocytes of the epidermal dermal keratinocytes, which is the active ingredient of the water-object (4) of the present invention, is proliferated, and the lion is prevented from ameliorating the delay of metabolic renewal, preventing aging, ultraviolet irradiation Since the skin of the epidermis is flattened and the aging skin acts again, it can be used as a skin external composition for preventing aging. I ^ Collagen with the water content of the sucrose as the active ingredient of the fx, the 200932756 promoter is used to improve the tension and impurities of the skin, and the lion can be expected to prevent and improve the leveling and relaxation. Anti-lang skin external composition is used. [Synthesis of Saccharomyces cerevisiae glycoside] The spirulina milk glycoside was synthesized according to the method of Helferich. _ In the presence of air, make water _ 宾 (3. Gg, 6. and Xin Yi waking base ^ lactose (6 · 3g, 9. 2mol) in 1_ of the two gas a hydox - acetonitrile (1: Bu v / v) In the granules, 14 ml of boron trifluoride dimethyl scale complex, and 1 M at room temperature ® yna. After the reaction, the solution was cooled with ice and a saturated aqueous solution of sodium carbonate was added. The extracting treatment was carried out twice with 150 ml of a two-gas ablation process. After the treatment with anhydrous sodium sulfate, the extraction solvent was removed by an evaporator. The triethylamine-nonanol-water (1 ··δ: υ was reacted at 35 〇 for 3 ,, Then, the solvent was removed by an evaporator. Purification was carried out using B0NDESIL_cl8 (Varian) to obtain a water-squeezed 4-negative lactoside (1. 〇g, yield 2% by weight). The MS spectrum of the obtained silybin milk glycoside was obtained. Confirmation of 'detection of mass spectrum peak of [M+H]+ : 8〇7 5 . ® [Synthesis of silibinin maltose glycoside] Synthesis of silibinin maltose glycoside according to Helferich method. In the presence of 'silibinin (3.0 g, 6.2 inol) and octyl-indole-D-maltose (β. 3g, 9.2 mol) in 180 ml of dichloromethane-acetonitrile (1: 1, v / v) solvent, and trifluoride The dimethyl ether complex (1.14 ml, 12.4 mmol) was stirred at room temperature for 19 hours. After the reaction was completed, ice-cooled, a saturated aqueous solution of sodium hydrogencarbonate was added, and extracted twice with 150 ml of dioxane. After the anhydrous sulfur 200932756 sodium sulphate treatment (four) hair removal remove the extraction solvent. The ethamine-methanol-water (1:8: 〇 at 35. 匸 reaction continent hours, then use the solvent to remove. 帛 _ESIL-C18 (Varian Purification was carried out to obtain a gas 麦 ( ( 四 四 Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Mass spectrometry peak of 5. [Example 1] Water bathing test 1 · Experimental method Weigh the appropriate amount of water philips, water (four) broth glycoside, and water saponin malt glycoside in 1. 5 ml of the tester (the following will Water Rybin is abbreviated as SB, water, fine milk, sugar, body, SBL, Spirulina, malt, glycoside, abbreviated as Μ), and added pure. Water purification 'matched into various concentrations' by visual inspection It is judged whether the appearance transparency and the centrifugation at room temperature 〇5_rpm, 5min), and whether it is water-soluble in SB. Poor, weighed small amount of water was added drop grant is stirred for about 1 hour ❹ grant 'to stop the mixing operation! Sink is found, it is determined that the house after hours was dissolved in a beaker. TABLE 1
---- 化合物名稱/濃度(mM) .__ 0.01 0.1 1 —----- 50 60 70 100 SB ---- △ X X X X X X SBL 〇 〇 〇 〇 △ X X SBM 〇 〇 〇 〇 △ X ’ X 〇:無析出X:析出△:不能判定 12 200932756 實驗的結果,發現與SB相比’ SBL、SBM兩者的水溶性急劇提 高,水溶性提高至約5000倍以上。未能檢測出SBL、SBM兩者的 溶解性的優劣。SB濃度0. OlmM相當於0. 0005% (w/v)。SBL及 SBM 的濃度 50mM、60mM 分別相當於 4. 1% (w/v)、4. 9% (w/v)。 因此’如果用質量/容量%來比較SB和SBL、SBM的溶解性,則SBL、 SBM的溶解性與SB相比提高約10, 000倍。在水溶性型的皮膚外用 組合物等製劑中,以往含有〇. 0005% (w/v)濃度的SB都很困難, β 而現在可含有4.1% (w/v)濃度的SBL,可含有5. 0% (w/v)濃 度的 SBM。此外,SBL、SBM 的濃度 0. OlmM 相當於 〇. 0008% (w/v;>。 〔實施例2〕 表皮角質細胞分化抑制試驗、增殖維持作用 1.實驗材料 1.1人體正常表皮角質細胞 ❷ 将人體正常表皮角質细胞NHEK (Asahi Techno Glass)在表 皮角質细胞用培養基:KGM (Asahi Techno Glass)中用37°C-5 % C〇2培養箱進行培養。本實驗使用繼代數為3〜5代的細胞。 1.2 KGM (表皮角質細胞用培養基) KGM是在表皮角質细胞基礎培養基上添加人體上皮细胞增殖 因子(0. lng/ml )、胰島素(5. Ο/zg/ml)、氫化可的松(〇. 5/zg/nii)、 慶大徵素(50//g/ml)、兩性徽素B (50/ig/ml)、牛腦下垂體萃取 200932756 液(2ml)後的培養基。將以水飛薊賓配糖體為代表的試樣添加在 細胞中時,使用僅除去牛腦下垂體萃取液的KGM培養基進行實驗。 1.3添加試樣 將水飛箣賓(SB)、水飛薊賓麥芽配糠體(SBM)、水飛莉賓乳 配糖體(SBL)溶解在DMS0 (二甲亞砜:和光純藥)中,以各種濃 度添加。 2. 實驗方法 2.1表皮角質細胞分化抑制試驗 將NHEK懸浮於KGM中使其為5xl04/ml,以4ml/孔接種於6 孔培養板上,培養24小時,使細胞粘結在培養板上。用除去牛腦 下垂體萃取液的添加各化合物的KGM以4ml/孔進行處理,每2天 更換培養基’培養8〜10天。每天微驗察形態,在麵處 理的對照細胞顯示出分化跡象的形態變化(扁平化)時,進行照 相,結束培養。 2· 2表皮角質細胞增殖維持試驗 將上述實驗巾獲得的細胞通過胰蛋自酶處雜培養板上剝下 後’懸浮於KGM中使其為2. 5_V〇a。將細胞懸浮液以2ml/孔接 種於24孔培養板上’每2天更換培養基,培養8天。培養後,將 瞧通過騰蛋㈣處理從培養板上剝下,料爾特計數器 (Beckman-Coulter)測定細胞數。 3. 實驗結果 200932756 3.1表皮角質細胞分化抑制試驗 獲得的實驗結果如圖1所示,該圖是細胞的顯微鏡照片。 DMS0處理的比較對照組Control以及SB 3(在添加水飛 薊賓3#M的培養基中培養)中’表皮角質細胞發生扁平化,亂示 出分化跡象的形態變化*。與此相對,SBM3eM、SBL3//M中沒有出 現分化跡象的形態。在分別添加的SB、SBL、SBM的培養基 中培養時’表皮角質細胞的分化全部受到抑制。SB、SBL、SBM均 © 具有表皮角質細胞的分化抑制作用,但與SB相比,SBM、SBL的 表皮角質細胞分化抑制效果優異。 3. 2表皮角質細胞增殖維持試驗 在上述表皮角質細胞分化抑制試驗中,如果分化得到抑制, 則細胞應維持增殖能力,通過繼代操作可依次增殖。被誘導分化 的細胞,因為分化是不可逆的反應,所以不能增殖。 於是將上述試驗獲得的細胞進行繼代培養,通過測定增殖的 ® 細胞數量來檢驗維持的增殖能力。 試樣漢度為時,添加SB後的細胞----Compound name/concentration (mM) .__ 0.01 0.1 1 —----- 50 60 70 100 SB ---- △ XXXXXX SBL 〇〇〇〇△ XX SBM 〇〇〇〇△ X ' X 〇 : No precipitation X: Precipitation Δ: The result of the experiment of 200932756 was not determined. It was found that the water solubility of both SBL and SBM was sharply improved and the water solubility was improved to about 5,000 times or more compared with SB. The solubility of both SBL and SBM could not be detected. The SB concentration is 0. OlmM is equivalent to 0.005% (w/v). The concentrations of SBL and SBM 50 mM, 60 mM were equivalent to 4. 1% (w/v) and 4.9% (w/v), respectively. Therefore, if the solubility of SB, SBL, and SBM is compared by mass/capacity %, the solubility of SBL and SBM is increased by about 10,000 times compared with SB. In a preparation such as a water-soluble skin external composition, SB having a concentration of 〇. 0005% (w/v) has been difficult in the past, and β can now contain a SBL of 4.1% (w/v) concentration, which may contain 5 . 0% (w/v) concentration of SBM. Further, the concentration of SBL and SBM is 0. OlmM is equivalent to 000. 0008% (w/v; > [Example 2] Epidermal keratinocyte differentiation inhibition test, proliferation maintenance effect 1. Experimental material 1.1 Human normal epidermal keratinocyte ❷ The human normal epidermal keratinocyte NHEK (Asahi Techno Glass) was cultured in an epidermal keratinocyte culture medium: KGM (Asahi Techno Glass) in a 37 ° C - 5 % C 2 incubator. The experiment used a sub-algebra of 3 to 5 Generation of cells. 1.2 KGM (the medium for epidermal keratinocytes) KGM is a human epithelial cell proliferation factor (0. lng/ml), insulin (5. Ο/zg/ml), hydrogenated on the basal medium of epidermal keratinocytes. The medium after pine (〇. 5/zg/nii), Qingda Zhengsu (50//g/ml), amphotericin B (50/ig/ml), and bovine pituitary gland extracting 200932756 liquid (2 ml). When a sample represented by a silibinin glycoside is added to a cell, the experiment is carried out using KGM medium in which only the bovine brain pituitary extract is removed. 1.3 Adding a sample to Silibinin (SB) and water fly蓟宾麦芽配糠 (SBM), 水飞莉宾乳糖 (SBL) dissolved in DMS0 (two In the sulfoxide: Wako Pure Chemicals, it was added at various concentrations. 2. Experimental method 2.1 Epidermal keratinocyte differentiation inhibition test NHEK was suspended in KGM to make 5×10 4 /ml, and inoculated into 6-well culture plates at 4 ml/well. The cells were incubated for 24 hours, and the cells were adhered to the culture plate. KGM supplemented with each compound was removed at 4 ml/well, and the medium was changed every 2 days for 8 to 10 days. Morphology, when the surface-treated control cells showed morphological changes (flattening) of signs of differentiation, photographing was performed, and the culture was terminated. 2. 2 Epidermal keratinocyte proliferation maintenance test The cells obtained from the above test tissues were passed through the egg-like enzyme. After the plate was peeled off, it was suspended in KGM to be 2. 5_V〇a. The cell suspension was seeded at 2 ml/well on a 24-well culture plate. The medium was changed every 2 days and cultured for 8 days. After the culture, The 瞧 was peeled off from the culture plate by the egg (4) treatment, and the number of cells was determined by a Beckman-Coulter. 3. Experimental results 200932756 3.1 Experimental results obtained by the epidermal keratinocyte differentiation inhibition test are shown in Fig. 1, It is a micrograph of the cells. In comparison with the control group Control and SB 3 (cultured in the medium supplemented with silybin 3#M) of DMS0 treatment, the epidermal keratinocytes were flattened, and the morphological changes of signs of differentiation were revealed. On the other hand, there were no signs of differentiation in SBM3eM and SBL3//M. When cultured in a medium of SB, SBL, or SBM added separately, the differentiation of epidermal keratinocytes was all inhibited. SB, SBL, and SBM all have a differentiation inhibitory effect on epidermal keratinocytes, but SBM and SBL have superior epidermal keratinocyte differentiation inhibitory effects compared with SB. 3. 2 Epidermal keratinocyte proliferation maintenance test In the above-described epidermal keratinocyte differentiation inhibition test, if differentiation is inhibited, the cells should maintain proliferative ability and can be sequentially propagated by subculture. Cells that are induced to differentiate cannot proliferate because they are irreversible reactions. Then, the cells obtained in the above test were subcultured, and the proliferative ability maintained was examined by measuring the number of proliferating ® cells. When the sample is at an hour, the cells after adding SB are added.
細胞數增加到2.1倍,SBL與不添加 其結果如圖2所示,試樣濃度j 增瘦能力幾乎沒有被維持,Sbm與; 到1· 8倍,SBL與不添加試樣相比 ,i 200932756 試樣相比,細胞數增加到L8倍,確認有細胞增殖能力的維持致 果。與SB相比,可知SBM、SBL的細胞增殖能力的維持效果高。 〔實施例3〕 I型膠原蛋白產生促進作用 1. 實驗材料 L1人體皮膚纖維芽細胞 將人體皮膚纖維芽細胞CCD1074SK(大日本住友製藥)在d_Mem 中用37 C- 5 % C〇2培養箱培養。在本實驗中利用繼代數為丨〇〜 15代的細胞。The number of cells increased to 2.1 times, and the results of SBL and no addition are shown in Fig. 2. The sample thickness j thinning ability is hardly maintained, Sbm and; to 1.8 times, SBL is compared with no sample added, i Compared with the sample of 200932756, the number of cells increased to L8 times, and it was confirmed that the cell proliferation ability was maintained. Compared with SB, it can be seen that the maintenance effect of cell proliferation ability of SBM and SBL is high. [Example 3] Type I collagen production promoting effect 1. Experimental material L1 Human skin fibroblast cells Human skin fibroblasts CCD1074SK (Daichi Sumitomo Pharmaceutical Co., Ltd.) were cultured in d_Mem with 37 C-5% C〇2 incubator . In this experiment, cells with sub-algebras of 丨〇-15 generations were used.
1.2 D-MEM D-MEM,在D-MEM基礎培養基(GIBC0)中添加牛胎兒血清 (Hyclone)為10%並使用。此外,在處理試樣時,使用不添加牛 胎兒血清的D-MEM進行實驗。 2. 實驗方法 將人體皮膚纖維芽細胞CCD1074SK懸浮於含有1〇%牛胎兒血 清的D-MEM培養基中,使其為3xlGVml,接種-於咖培養皿 中,培養24顿’使細祕結在培養板上。將鱗基更換為將在 DMS0中鑛的各離以各濃度添加科添科胎兒血清的㈣μ 培養基。在賴培養基48小時伽收細胞培魏,制雜裝置 濃縮培養液。濃縮躺5〇_以下後,進行蛋自質定量,收集蛋 200932756 白質後,作為細胞培養液濃縮試樣’用於蛋白質印跡分析(western blotting)° 使用每1泳道l〇gg的蛋白質,用SDS_pAGE分離後,轉印到 硝酸纖維素膜上。將轉印後的硝酸纖維素膜浸潰在封閉溶液(在 含有〇. 1%聚氧乙烯(20)山梨醇酐單月桂酸酯的pBS中溶解脫脂 奶粉為5 %濃度的溶液)中’4°c封閉-晝夜。用洗蘇液(含有( %聚氧乙烯(20) 6梨醇酐單月桂酸㈣pBS)洗;條後,浸潰於一 © -欠抗體[用洗條液製備成5〇〇ng/ml的I型膠原蛋白的多克隆抗體 (Rockland)]中,室溫下反應時。絲後,浸潰於二次抗體 (用洗滌液製備成25〇ng/ml的辣根過氧化物酶標記抗免疫球蛋白 G)中,室溫下反應1小時。洗蘇後,使用Ea pius蛋白質印跡 (western blotting detection reagent) (Amersham Biosciences公司)進行檢測。 實驗結果 ® 貫驗結果,確認與SB相同’ SBL、SBM兩者均有i型膠原蛋白 產生促進作用。實驗結果如圖3所示。 將獲得的條帶的強度通過程式軟體Image ;進行數位化的結 果如表2所示,將DMS0處理時的丨型膠原蛋白產生量作為丨時的 比較產生量如圖4所示。 表2 2009327561.2 D-MEM D-MEM, 10% fetal serum (Hyclone) was added to D-MEM basal medium (GIBC0) and used. Further, when the sample was processed, the experiment was carried out using D-MEM without adding bovine fetal serum. 2. Experimental method Human skin fibroblast CCD1074SK was suspended in D-MEM medium containing 1% fetal calf serum, which was made into 3xlGVml, inoculated in a culture dish, and cultured for 24 tons. On the board. The squama was replaced with (iv) μ medium in which each of the minerals in DMS0 was added to each of the concentrations of Kodak fetal serum. The medium was incubated in the medium for 48 hours, and the culture medium was concentrated. After concentrating 5 〇 _ or less, the egg was quantified, and the egg 200932756 white matter was collected, and the sample was concentrated as a cell culture solution for western blotting. Using a protein of 1 泳gg per lane, using SDS_pAGE After separation, it was transferred onto a nitrocellulose membrane. The transferred nitrocellulose membrane was immersed in a blocking solution (in a pBS containing %. 1% polyoxyethylene (20) sorbitan monolaurate dissolved in skim milk powder to a 5% concentration solution) °c closed - staying up late. Wash with sodium sulphate (containing (% polyoxyethylene (20) 6 linoleic acid monolaurate (tetra) pBS); after the strip, immerse in a _ under antibody [prepared into 5 ng / ml with stripping solution In the polyclonal antibody of type I collagen (Rockland), at room temperature, after silking, impregnated with secondary antibody (prepared with 25 ng/ml of horseradish peroxidase-labeled anti-immunization with washing solution) In the globulin G), the reaction was carried out for 1 hour at room temperature, and after washing with a Western blotting detection reagent (Amersham Biosciences), the results of the test were verified to be the same as the SB. Both SBM have the promotion of i-type collagen production. The experimental results are shown in Fig. 3. The intensity of the obtained band is passed through the program software Image; the results of digitization are shown in Table 2, and the D of DMS0 treatment The amount of collagen produced as a comparative yield when 丨 is shown in Figure 4. Table 2 200932756
DMSQ SB3|jiVl SB1〇mJV1 SBM3_ SBMIC^JVI SBL3mJV1 SBLICVJVl ^5.064 831656 8397 9S977 116102 &4.068 107.797 rBlative irtensitv 1.00 1.86 1.86 ZC9 258 2C9 239 表明SB、·、SBL均具有I型膠原蛋白產生促進作用。與部 相比,識、狐的1郷妓自私她卿。制是試樣濃 度為1MM時’ SBM、SBL的作用效果大,確認高濃度時有顯著的 作用效果。 〔貫施例4〕 紫外線照射所致的水分喪失的抑制作用皺紋的形成抑制作 用 L實驗材料、器具 實驗動物無毛小鼠H〇s;HRl早5周齡(星野實驗材料) L2紫外線照射裝置 紫外線 A 波(FL32SBL/DMR :(株式會社)clinical supply 製) 200932756 紫外線B波(FL32SE/DMR :(株式會社)c 1 i n i ca 1 supp丨y製) 1. 3經皮水分喪失量測定裝置DMSQ SB3|jiVl SB1〇mJV1 SBM3_ SBMIC^JVI SBL3mJV1 SBLICVJVl ^5.064 831656 8397 9S977 116102 &4.068 107.797 rBlative irtensitv 1.00 1.86 1.86 ZC9 258 2C9 239 indicates that SB, ·, and SBL all have type I collagen production promoting effects. Compared with the ministry, the ignorance of the fox and the fox is selfish. When the sample concentration is 1 MM, the effect of SBM and SBL is large, and it is remarkable when a high concentration is confirmed. [Example 4] Inhibition of water loss by ultraviolet irradiation, inhibition of formation of wrinkles L experimental materials, apparatus, experimental animals, hairless mice, H〇s; HR1, 5 weeks old (Hoshino experimental material) L2 ultraviolet irradiation device Ultraviolet A wave (FL32SBL/DMR: manufactured by Clinical Supply Co., Ltd.) 200932756 Ultraviolet B wave (FL32SE/DMR: manufactured by c 1 ini ca 1 supp丨y) 1. 3 Percutaneous water loss measuring device
Vapometer ( k-science 公司製) 1.4複製品採集器具及複製品分析系統Vapometer (manufactured by k-science) 1.4 Replica collection instrument and replica analysis system
(有)Asahibiomed公司製的反射型複製品採集套盒及複製品 分析系統ASA-03RXD 2. 實驗方法 © 2.1飼養環境 在25°C±2°C、濕度50%±5%、可分別自由攝取作為食躺飼 料MR、自來水的常規飼養環境下飼養。 將每一組分為5隻’在同一籠中飼養。 • 曰照為上午7點〜下午7點,每12小時設定晝夜。 2.2紫外線照射 將無毛小乳Hos;HRl ,訓化1周時間後開始照射紫外線。紫外 ® 線照射時將無毛小鼠移到專用籠子内,每1組各照射UVB20mJ/cm2 及UVAlOJ/cm2的紫外線。照射在星期一、星期三、星期五,每週 3天迴圈,實施1〇周時間,共照射30次紫外線。 2. 3組設定 紫外線照射後’ 30分鐘以内在小鼠背部皮膚的全部表面上用 100//L的SB、SBL、SBM曱醇溶液或溶劑(曱醇)進行處理。將 SB、SBL、SBM塗布的濃度分別設定為丨〇%、〇 3%、〇 1%這3 200932756 種對於所有組進行紫外線㈣卜對於僅塗布溶劑甲醇的小鼠, 為紫外線未照射組及紫外線照射組。使用甲醇作溶劑是為了溶 解SB在曱醇中識、狐為⑼濃度時也完全溶解但π僅在 Z守才凡王,谷解,為〇. 3%時有若干析出,為1%時發現充不 办物。即使SB甲醇溶液中發現有不溶物時,也直接用於實驗。 2. 4經皮水分喪失量的測定 經皮水分喪失量的测定,使用Vap〇Meter ( Keys1;〇ne entif ic么司製)’對於從背部的尾根延向頭部方向、從腰❹ 椎向右侧G· 5αη的部位測定3次,求出平均值。測定端末的開口 部使用Nail模型(使開口部變窄,對應小鼠皮膚窄的範圍),每i -人測疋時間需要約19秒。測定日在紫外線照射1〇周後進行。 2. 5複製品圖像分析 為了正確把握皺紋的形成,採集複製品。複製品圖像分析使 用反射用複製品分析系、統ASA-Q3RXD((有)Asahibiomed製)進行。 使用ASA-03RXD ’通過從27度的角度向採集的複製品上照射平行 Ο 光(LED光源)’將與獲得的皺紋形狀相應的陰影圖像通過CCD照 相機攝像,輸人到電腦中並進行圖像處理,計測複製品表面的皱 紋體積率(#m3/mm2/100)。 2. 6統計分析 試驗結果帛平均值±鮮偏差(S.D·)表示,顯著性差異檢驗 疋通過Bartlett 檢-^x法進行同方差性檢驗。沒有拒絕同方差性假 20 200932756 设時,進行Dunneti:多重檢驗,拒絕同方差性假設時作為參考資 料進行Dunnett多重檢驗。 3.試驗結果 3.1體重變化、外觀觀察 10周時間照射結束後’各組間在體重變化方面沒有明顯差 別。也沒有顯示嚴重病變的小鼠。 對小鼠皮膚的外觀進行觀察的結果,發現組2的紫外線照射 ® 曱醇處理組有皺紋形成,而組4的0. 3%水飛薊賓塗布組、組6〜 組8的全部SBM塗布組、組9〜組11的全部SBL塗布組中,均有 皺紋抑制作用。 3. 2經皮水分喪失量 作為皮膚粗糙的指標,在紫外線照射1〇周時間後使用 VapoMeter測定各組的水分喪失量。結果如表3和圖5所示。 與組1紫外線未照射組相比,組2的紫外線照射組的經皮水 ® 分喪失f增尚。組3〜組11的水飛莉賓(SB)、水飛薊賓配糖體 (SBM'SBL)塗布組,顯著性水準1%以下顯著抑制了經皮水分喪 失量的上升。 將1組(备、外線非照射、曱醇塗布)的水分喪失量作為〇%, 將2組(备、外線照射、曱醇塗布)的水分喪失量作為1⑽%時,3 〜5組(备、外線照射、部〇. 1〜1%塗布)的水分喪失量為沈〜π % , 6〜8組(紫外線照射、SBM 〇1〜1%塗布)的水分量為 200932756 2W ’ 9〜丨丨組(紫外賴射、狐Q. 塗布)的水分量為 24〜27% ’通過添加SB、SBM、SBL,抑制了水分喪失量的上升。 ,別是水«賓配糖體的SBM、SBL的抑制水分喪失量上升的效果 向。總之具有改善日曬所致的皮膚粗糙的致果。 表3 " 組No· UV 塗布 濃 % (w/v) 水分蒸發量 (g/m2h ) —-— 水分蒸發量比 (%) 1 非照射 甲醇 ------ 11.8 0 — 2 照射 甲醇 - ~~ — 25.0 100 3 照射 SB甲醇溶液 0.1 ---- 19. 2 56 4 m hx. SB曱醇溶液 0.3 -----— 阳、射 15.2 2B 5 照射 SB曱醇溶液 l7〇 ~—---- 21.8 76 6 照射 SBM甲醇溶液 ------- 0.1 14. 4 20 7 照射 SBM甲醇溶液 0.3 ---- 14. 6 21 8 照射 SBM甲醇溶液 '~~~----- 1.0 13.2 11 9 照射 SBL甲醇溶液 0.1 15.0 24 10 照射 SBL甲醇溶液 0.3 -------- 15.3 27 11 照射 SBL甲醇溶液 1.0 ------ 15.0 24 ---(Yes) Reflective replica collection kit and replica analysis system manufactured by Asahibiomed Co., Ltd. ASA-03RXD 2. Experimental method 2.1 2.1 Feeding environment at 25 °C ± 2 °C, humidity 50% ± 5%, freely ingestible It is raised in a conventional breeding environment as a food feed MR and tap water. Each component was 5 ‘in the same cage. • The photo is from 7 am to 7 pm and is set to stay up every 12 hours. 2.2 UV irradiation The hairless small milk Hos; HRl, after training for 1 week, began to irradiate ultraviolet rays. Hairless mice were transferred to a special cage under UV-ray irradiation, and each group was irradiated with UVB of UVB20 mJ/cm2 and UVAlOJ/cm2. Irradiation was performed on Monday, Wednesday, and Friday, and was cycled 3 days a week for 1 week, and 30 times of ultraviolet rays were irradiated. 2. Three sets of settings After UV irradiation, the surface of the back skin of the mouse was treated with 100//L SB, SBL, SBM sterol solution or solvent (sterol) within 30 minutes. The concentrations of SB, SBL, and SBM coating were set to 丨〇%, 〇3%, 〇1%, respectively. 3 200932756 For all groups, UV (four) for mice coated with solvent methanol, UV-irradiated group and UV Irradiation group. The use of methanol as a solvent is to dissolve the SB in the sterol, and the fox is completely dissolved at the concentration of (9), but π is only in the Z shoufan, the glutinous solution, and the 解. 3% when there is some precipitation, which is found at 1%. I can't do anything. Even when insoluble matter was found in the SB methanol solution, it was directly used for the experiment. 2. 4 Determination of transepidermal water loss The measurement of transepidermal water loss is performed using Vap〇Meter (Keys1; 〇ne entific system)' for the tail from the back to the head direction, from the lumbosacral vertebrae The portion of the right G·5αη was measured three times, and the average value was determined. The Nail model was used to measure the opening at the end of the measurement (the opening was narrowed to correspond to the narrow range of the mouse skin), and it took about 19 seconds for each i-human measurement time. The measurement day was carried out after 1 week of ultraviolet irradiation. 2. 5 Replica image analysis In order to correctly grasp the formation of wrinkles, collect replicas. The replica image analysis was carried out using a reflection replica analysis system, ASA-Q3RXD (manufactured by Asahibiomed). Use the ASA-03RXD 'to illuminate the captured replica from a 27 degree angle to illuminate parallel light (LED light source)'. The shadow image corresponding to the obtained wrinkle shape is imaged by a CCD camera, input to a computer and graphed Like the treatment, the wrinkle volume ratio (#m3/mm2/100) on the surface of the replica was measured. 2. 6 Statistical analysis The test results 帛 mean ± fresh deviation (S. D ·) indicates that the significant difference test 疋 is tested by the Bartlett test-^x method for homoscedasticity test. No rejection of homosexuality leave 20 200932756 At the time of the Dunneti: multiple test, the Dunnett multiple test was used as a reference material when rejecting the same variance hypothesis. 3. Test results 3.1 Changes in body weight and appearance After the end of the irradiation for 10 weeks, there was no significant difference in body weight change between the groups. There were also no mice showing severe lesions. As a result of observing the appearance of the mouse skin, it was found that the ultraviolet irradiation® sterol treatment group of group 2 had wrinkle formation, while the group 4 of 0.3% silibin coating group, group 6 to group 8 of all SBM coating. In all of the SBL-coated groups of the group, the group 9 to the group 11, wrinkle suppression was observed. 3. 2 Percutaneous water loss As an indicator of skin roughness, the amount of water loss in each group was measured using VapoMeter after 1 week of ultraviolet irradiation. The results are shown in Table 3 and Figure 5. Compared with the group 1 ultraviolet non-irradiated group, the percutaneous water fraction of the ultraviolet irradiation group of group 2 lost the increase of f. In group 3 to group 11 of the water silibin (SB) and the silybin sucrose (SBM'SBL) coating group, the significant level of 1% or less significantly inhibited the increase in transepidermal water loss. When the water loss amount of one set (preparation, external line non-irradiation, and decyl alcohol coating) is 〇%, and the water loss amount of two sets (preparation, external irradiation, and decyl alcohol coating) is 1 (10)%, 3 to 5 groups (prepared) The amount of water loss in the outer line irradiation, the part 〇. 1~1% coating) is Shen~π%, and the water content of the 6~8 group (ultraviolet irradiation, SBM 〇1~1% coating) is 200932756 2W '9~丨丨The moisture content of the group (ultraviolet radiation, fox Q. coating) was 24 to 27%. By adding SB, SBM, and SBL, the increase in water loss was suppressed. In addition, it is the effect of SBM and SBL of water-based saccharide body to suppress the increase in water loss. In short, it has the effect of improving the roughness of the skin caused by the sun. Table 3 " Group No. UV Coating Concentration (w/v) Moisture Evaporation (g/m2h) —-— Moisture Evaporation Ratio (%) 1 Non-irradiation Methanol —— 11.8 0 — 2 Irradiation of Methanol - ~~ — 25.0 100 3 Irradiation SB methanol solution 0.1 ---- 19. 2 56 4 m hx. SB sterol solution 0.3 ----- 阳, shot 15.2 2B 5 Irradiation SB sterol solution l7 〇~ ---- 21.8 76 6 Irradiation of SBM methanol solution ------- 0.1 14. 4 20 7 Irradiation of SBM methanol solution 0.3 ---- 14. 6 21 8 Irradiation of SBM methanol solution '~~~---- - 1.0 13.2 11 9 Irradiation of SBL methanol solution 0.1 15.0 24 10 Irradiation of SBL methanol solution 0.3 -------- 15.3 27 11 Irradiation of SBL methanol solution 1.0 ------ 15.0 24 ---
3· 3皺紋體積率 1〇周時間照射結束後’為了正確把雛紋的形成,收集複製 品’通過圖像分析計測複製品表面的皺紋體積率("心_2/1〇〇)。 結果如表4、圖6所示。 實施Dunnett的顯著性差異檢驗的結果,贿於組2 (紫外線 22 200932756 照射f醇塗布),組1 (紫外線未照射甲醇塗布)、組4 (紫外線昭 射SB 〇屬塗布)、組7 (紫外線照射識〇篇塗布)、組ii (紫 外線照射SBL 1. 〇%塗布),分別在顯著性水準5 %以下赦紋體積 得到顯著抑制。 表4 組No.3·3 Wrinkle volume ratio 1 After the end of the irradiation period, 'To collect the replicas correctly, collect the replicas' and measure the wrinkle volume ratio of the surface of the replica by image analysis ("heart_2/1〇〇). The results are shown in Table 4 and Figure 6. The results of Dunnett's significant difference test were carried out, bribe in group 2 (UV 22 200932756 irradiated f alcohol coating), group 1 (ultraviolet non-irradiated methanol coating), group 4 (ultraviolet SB 〇 〇 coating), group 7 (ultraviolet The illuminating volume was significantly suppressed at a significant level of 5% or less, respectively, in Group ii (UV-irradiated SBL 1. 〇% coating). Table 4 Group No.
UV 塗布 濃度 % (w/v) Ο Ο 10 —— 11 非照射 照射 照射 照射 — 一 照射 照射 — 照射 照射 皺紋體積率 (;zm3/mmVl〇〇) 甲醇 曱醇 SB甲醇溶液 SB曱醇溶液 SB甲醇溶液 SBM甲醇溶液 SBM曱醇溶液 SBM甲醇溶液 SBL甲醇溶液 SBL甲醇溶液 SBL甲醇溶液 12 17 20 19 14 〔處方例1化妝水〕 ^ 質量% •水_賓乳配糖體 0 3 :.(一縮)二甘油 由 5.0 •1,3〜丁二醇 23 200932756 4.(一縮)二丙二醇 3.0 5.氫氧化鉀 適量 6.檸檬酸 適量 7.純淨水 剩餘_ (製法) 在7中溶解1〜6。 〔處方例2乳液〕 質量% 1.水飛薊賓麥芽配糖體 0.3 2.氫化大豆礙脂 0.7 3.十聚甘油硬脂酸酯(HLB 12) 2.0 4.甘油 8.0 5.橄欖油 8.0 6.山蝓醇 1.0 7.(—縮)二丙二醇 8.0 8.聚羧乙烯 0.1 9.黃原膠 0.2 10.氫氧化鉀 適量 11.擰檬酸 適量 12.純淨水 剩餘UV coating concentration % (w/v) Ο Ο 10 —— 11 Non-irradiation irradiation - One irradiation - Irradiation wrinkle volume ratio (;zm3/mmVl〇〇) Methanol sterol SB methanol solution SB sterol solution SB methanol Solution SBM methanol solution SBM sterol solution SBM methanol solution SBL methanol solution SBL methanol solution SBL methanol solution 12 17 20 19 14 [Prescription example 1 lotion] ^% by mass • Water _Bin milk glycoside 0 3:. ) Diglycerol consists of 5.0 •1,3~butanediol 23 200932756 4. (monocondensed) dipropylene glycol 3.0 5. Potassium hydroxide amount 6. citric acid amount 7. Purified water remaining _ (preparation method) Dissolve 1 in 7 6. [Prescription Example 2 Emulsion] Mass % 1. Silibinin malt glycoside 0.3 2. Hydrogenated soybean malaise 0.7 3. Decaglyceryl stearate (HLB 12) 2.0 4. Glycerin 8.0 5. Olive oil 8.0 6. Beryl alcohol 1.0 7. (-) dipropylene glycol 8.0 8. Carbopol 0.1 9. Xanthan gum 0.2 10. Potassium hydroxide amount 11. Molybdic acid amount 12. Pure water remaining
❹ 24 200932756 (製法) 將1〜4及7〜12在80°C下加溫溶解。在其中加入已加溫至約 ❹❹ 24 200932756 (Preparation method) 1 to 4 and 7 to 12 are dissolved at 80 ° C. Adding to it has been heated to about ❹
80°C的5、6,用均質器攪拌混合,冷卻至30°C ,獲得乳液。 〔處方例3保濕美容液〕 質量% 1.水飛薊賓乳配糖體 0.2 2.氫化大豆填脂 0.6 3.十聚甘油單油酸S旨(HLB 12) 1.5 4.甘油 7.0 5.1,3-丁二醇 5.0 6.聚乙二醇4000 0.1 7.角鯊烷 5.0 8.砍嗣 0.5 9.二(植物留醇/辛基十二醇)月桂醯谷氨酸酯 0.2 10.黃原膠 0.3 11.氫氧化鉀 適量 12.擰檬酸 適量 13.純淨水 剩餘 (製法) 將1及11〜13擾拌溶解,添加4〜6、10後加溫至80°C溶解。 25 200932756 在其中加入已加溫至約80°C的2、3、7〜9,冷卻至30°C,獲得保 濕美容液。 〔處方例4潤膚霜〕 — 質量% 0.5 10.0 〇 8.0 0.5 0.01 0.5 10.05 and 6 at 80 ° C, stirred and mixed with a homogenizer, and cooled to 30 ° C to obtain an emulsion. [Prescription Example 3 Moisturizing Beauty Liquid]% by mass 1. Silibinin milk with sugar body 0.2 2. Hydrogenated soybean fat 0.6. Decaglycerol monooleic acid S (HLB 12) 1.5 4. Glycerin 7.0 5.1, 3 - Butanediol 5.0 6. Polyethylene glycol 4000 0.1 7. Squalane 5.0 8. Chopped 0.5 9. Two (phytosterol / octyldodecanol) Laurel glutamate 0.2 10. Xanthan gum 0.3 11. Potassium oxyhydroxide amount 12. Capsitric acid amount 13. Purified water remaining (preparation method) Dissolve 1 and 11~13, add 4~6, 10, and then heat to 80 °C to dissolve. 25 200932756 2, 3, 7 to 9 which had been heated to about 80 ° C were added thereto, and cooled to 30 ° C to obtain a moisturizing cosmetic liquid. [Prescription Example 4 Moisturizer] —% by mass 0.5 10.0 〇 8.0 0.5 0.01 0.5 10.0
1. 水飛薊賓麥芽配糖體 2. (—縮)二甘油 3·(—縮)二丙二醇 4.1,2-戊二醇 5. L-絲氨酸 6. 十聚甘油二硬脂酸ϊ旨(HLB9. 5) 7. 十聚甘油單肉豆蔻酸酯(HLB14) 8. 撖欖油 9. 澳洲堅果油 10. 山输醇 11. 矽酮 12. 荷荷巴油1. Silibinin malt glycosides 2. (-) diglycerin 3 · (-) dipropylene glycol 4.1, 2-pentanediol 5. L-serine 6. Decaglycerol distearate (HLB9. 5) 7. Decaglycerol monomyristate (HLB14) 8. Eucalyptus oil 9. Macadamia oil 10. Mountain alcohol 11. Oxanone 12. Jojoba oil
13. 維生素E 14· SIMULGEL NS(SEPPIC 公司製) 15.黃原膠 26 20093275613. Vitamin E 14· SIMULGEL NS (manufactured by SEPPIC) 15. Xanthan gum 26 200932756
16.氫氧化鉀 適量 17.檸檬酸 適量 18.純淨水 剩餘 (製法) 將1及16〜18攪拌溶解,添加2〜5後加溫至約80°C溶解。 在其中添加已加溫至約80°C的6〜14,冷卻至30°C ,獲得潤膚霜£ 〔処方例5身體用乳液〕 質量% 1.水飛薊賓乳配糖體 0.2 2.PEG-60氫化蓖麻油(HLB14) 1.5 3.甘油 9.0 4.(一縮)二丙二醇 7.0 5.透明質酸鈉 0.001 6.流體石壤 10.0 7.矽酮 3.0 8.辛基十二炫醇 4.0 9.(丙烯酸/丙烯酸烷基(C10-30))酯共聚物 0.2 10.氫氧化鉀 適量 11.擰檬酸 適量 12.純淨水 剩餘 27 200932756 13.乙醇 2.5 (製法) 將1及10〜12攪拌溶解,添加2〜5、9後加溫至約80°C溶解。 在其中加入已加溫至約80°C的6〜8,冷卻至30°C,添加13,_獲 得身體用乳液。 〔處方例6按摩霜〕 質量% 1.水飛莉賓麥芽配糖體 0.05 2.甘油 10.0 3.(—縮)二甘油 2.0 4.丙二醇 7.0 5.十聚甘油單硬脂酸酯(HLB12) 1.0 6.乙基己酸十六醇酯 12.0 7.山喻醇 2.0 8.硬脂酸 0.5 9. SepinovEMT10(SEPPIC 公司製) 0.5 10.香料 適量 11.苯氧基乙醇 0.3 12.氫氧化鉀 適量 13.擰檬酸 適量16. Potassium hydroxide Appropriate amount 17. Citric acid Appropriate amount 18. Purified water Remaining (preparation method) Dissolve 1 and 16~18, add 2~5, and then heat to about 80 °C to dissolve. Add 6 to 14 which has been warmed to about 80 ° C, and cool to 30 ° C to obtain a moisturizer £ [Prescription Example 5 Body lotion] Mass % 1. Silibinin milk glycoside 0.2 2. PEG-60 hydrogenated castor oil (HLB14) 1.5 3. Glycerin 9.0 4. (monocondensed) dipropylene glycol 7.0 5. Sodium hyaluronate 0.001 6. Fluid stone soil 10.0 7. Anthrone 3.0 8. Octyldoxitol 4.0 9. (Acrylic/Acryl Acrylate (C10-30)) Ester Copolymer 0.2 10. Potassium Hydroxide Appropriate 11. Molybdenum Acid 12. Purified Water Remaining 27 200932756 13. Ethanol 2.5 (Manufacturing Method) 1 and 10~12 Stir and dissolve, add 2~5, 9 and then warm to about 80 ° C to dissolve. 6 to 8 which had been heated to about 80 ° C was added thereto, cooled to 30 ° C, and 13 was added to obtain a body lotion. [Prescription Example 6 Massage Cream]% by mass 1. Silibinin malt glycoside 0.05 2. Glycerin 10.0 3. (--) Diglycerin 2.0 4. Propylene glycol 7.0 5. Decaglycerol monostearate (HLB12 1.0 6. Cetyl ethylhexanoate 12.0 7. Samanol 2.0 8. Stearic acid 0.5 9. Sepinov EMT10 (manufactured by SEPPIC) 0.5 10. Flavor amount 11. Phenoxyethanol 0.3 12. Potassium hydroxide Appropriate amount 13. Moxibusty amount
28 200932756 14.純淨水 剩餘 (製法) 將1及11〜14攪拌溶解,添加2〜4後加溫至8CTC溶解。主 其中加入已加溫至約80°C的5〜9,冷卻至30°C,添加10,獲得 按摩霜。 〇 〔處方例7乳化型粉底〕 質量% 1. 水飛薊賓乳配糖體 0.1 2. 甘油 10. 0 3. (—縮)二丙二醇 8. 0 4.1,2-戊二醇 1.0 5.黃原膠 0.3 ® 6.聚甘油-2三異硬脂酸酯 1.0 7. 環甲石夕脂(Cyclome仕licone) 8.0 8. 矽酮 5.0 9. 異硬脂醇新戊酸醋 5. 0 10. 異硬脂酸 1.5 11. 山喻醇 0. 5 12. 糊精棕櫚酸酯 1.0 29 200932756 13.滑石 3.0 14.二氧化鈦 5. 0 15.氧化鐵紅 0.5 16.氧化鐵黃 1.4 17.氧化鐵黑 0.1 18.氫氧化鉀 適量 19.擰檬酸 適量 20.純淨水 剩餘 (製法) 將1及18〜20攪拌溶解,添加2〜5後加溫至約7(rc溶解。 接著添加充分粉碎的13〜17並搜拌混合。在其中加入已加溫至約 80°C的6〜12,冷卻至30°C ’獲得乳化型粉底。 【圖式簡單說明】 圖1係表示表皮角質細胞分化抑制試驗結果。 © 圖2係表示表皮角質細胞增殖維持試驗結果。 圖3係表示I型膠原蛋白產生促進試驗結果。 圖4係表示將圖3所示的條帶強度進行圖像處理數位化表示之圖 表。 圖5係表示測定經過紫外線照射試驗的小鼠的水分喪失量之數值。 圖6係表示經過紫外線照射試驗的小鼠的皮膚複製品表面之敏紋 30 200932756 體積率。 【主要元件符號說明】28 200932756 14. Purified water Remaining (preparation method) Stir and dissolve 1 and 11~14, add 2~4, and then heat to 8CTC to dissolve. Mainly, 5 to 9 which had been heated to about 80 ° C was added, cooled to 30 ° C, and 10 was added to obtain a massage cream. 〇 [Prescription Example 7 emulsified foundation]% by mass 1. Silibinin milk glycoside 0.1 2. Glycerin 10. 0 3. (--) dipropylene glycol 8. 0 4.1, 2-pentanediol 1.0 5. Yellow Raw rubber 0.3 ® 6. Polyglycerol-2 triisostearate 1.0 7. Cyclome lime 8.0 8. Anthrone 5.0 9. Isostearyl neopentanoic acid vinegar 5. 0 10. Isostearic acid 1.5 11. Ammonic alcohol 0. 5 12. Dextrin palmitate 1.0 29 200932756 13. Talc 3.0 14. Titanium dioxide 5. 0 15. Iron oxide red 0.5 16. Iron oxide yellow 1.4 17. Iron oxide black 0.1 18. Potassium Hydroxide Appropriate amount 19. Molybdenum acid amount 20. Purified water remaining (preparation method) Stir and dissolve 1 and 18~20, add 2~5, and then heat to about 7 (rc dissolve. Then add fully pulverized 13 ~17 and mix and mix. Add 6~12 which has been warmed to about 80 °C, and cool to 30 °C to obtain an emulsified foundation. [Simplified illustration] Figure 1 shows the inhibition test of keratinocyte differentiation of epidermis Results Fig. 2 shows the results of the epidermal keratinocyte proliferation maintenance test. Fig. 3 shows the results of the type I collagen production promotion test. Fig. 4 shows the band shown in Fig. 3. Fig. 5 shows the numerical value of the amount of water loss in the mouse subjected to the ultraviolet irradiation test. Fig. 6 shows the surface of the skin replica of the mouse subjected to the ultraviolet irradiation test. 200932756 Volume ratio. [Main component symbol description]
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008014361A JP2009173584A (en) | 2008-01-25 | 2008-01-25 | Silybin glycoside-containing external composition for skin |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200932756A true TW200932756A (en) | 2009-08-01 |
TWI527827B TWI527827B (en) | 2016-04-01 |
Family
ID=40922390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW098100842A TWI527827B (en) | 2008-01-25 | 2009-01-10 | External skin treatment composition comprising silybin glycosides |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2009173584A (en) |
KR (1) | KR20090082110A (en) |
CN (1) | CN101491485B (en) |
HK (1) | HK1129847A1 (en) |
TW (1) | TWI527827B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI488655B (en) * | 2009-04-24 | 2015-06-21 | 芳珂股份有限公司 | Aqueous solution of silybin glycocides and external skin treatment composition |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012082147A (en) * | 2010-10-07 | 2012-04-26 | Fancl Corp | Collagen gel-shrinking agent using silybin maltoside |
JP5584082B2 (en) * | 2010-10-07 | 2014-09-03 | 株式会社ファンケル | Proteasome activator |
JP2012082148A (en) * | 2010-10-07 | 2012-04-26 | Fancl Corp | Proteasome activator and carbonyl oxide protein inhibitor |
US9333230B2 (en) * | 2013-03-14 | 2016-05-10 | Mary Kay Inc. | Cosmetic compositions |
JP6614448B2 (en) * | 2016-03-31 | 2019-12-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | Anti-photoaging agent |
JP6614449B2 (en) * | 2016-03-31 | 2019-12-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | Anti-inflammatory agent |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI256893B (en) * | 2003-03-25 | 2006-06-21 | Fancl Corp | Composition for promoting production of type I collagen and/or elastin |
JP4954531B2 (en) * | 2005-10-31 | 2012-06-20 | 一丸ファルコス株式会社 | Peroxisome proliferator-responsive receptor activator |
-
2008
- 2008-01-25 JP JP2008014361A patent/JP2009173584A/en active Pending
-
2009
- 2009-01-10 TW TW098100842A patent/TWI527827B/en not_active IP Right Cessation
- 2009-01-12 KR KR1020090002370A patent/KR20090082110A/en not_active Application Discontinuation
- 2009-01-16 CN CN2009100004660A patent/CN101491485B/en not_active Expired - Fee Related
- 2009-10-19 HK HK09109617.5A patent/HK1129847A1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI488655B (en) * | 2009-04-24 | 2015-06-21 | 芳珂股份有限公司 | Aqueous solution of silybin glycocides and external skin treatment composition |
Also Published As
Publication number | Publication date |
---|---|
KR20090082110A (en) | 2009-07-29 |
HK1129847A1 (en) | 2009-12-11 |
CN101491485A (en) | 2009-07-29 |
CN101491485B (en) | 2013-01-09 |
JP2009173584A (en) | 2009-08-06 |
TWI527827B (en) | 2016-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI607764B (en) | External dermal composition for anti-ageing and method for producing the same | |
TW200932756A (en) | External skin treatment composition comprising silybin glycosides | |
US8647610B2 (en) | Use of melanin biosynthesis inhibitors from korean ginseng and the cosmetic composition containing thereof for skin whitening | |
US10092495B2 (en) | Use of a composition comprising avocado perseose in the protection of epidermal stem cells | |
CN113874044B (en) | Skin composition | |
CN102869339A (en) | Cosmetic composition containing oligopeptides | |
KR20170050062A (en) | Composition for Beverage and Cosmetics Containing Asiaticoside Madecassoside Asiatic acid Madecasic acid Extracted from Centella Asiatica Manufacturing Method Thereof | |
WO2017217695A1 (en) | Composition comprising alpha-garcinia mangostana, beta-garcinia mangostana, gamma-garcinia mangostana, or gartanin compound as effective ingredient for improving skin wrinkle or for moisturizing skin | |
CN110870880A (en) | Topical composition comprising pichia anomala and retinol | |
JP2008247783A (en) | External preparation composition | |
TWI488655B (en) | Aqueous solution of silybin glycocides and external skin treatment composition | |
CN114344289B (en) | Composition with anti-aging activity, preparation and application thereof | |
CN115487108A (en) | Caspase-1 activity inhibitor with antioxidant activity and application thereof | |
JP2004168732A (en) | Active oxygen-scavenging agent, inhibitor for synthesis promotion/decomposition of hyaluronic acid, and aquaporin synthesis promotor | |
JP2013040218A (en) | Silybin glycoside-containing skin care external composition | |
KR101663971B1 (en) | Composition for promoting the differentiation of human mesenchymal stem cell | |
JPWO2020138023A1 (en) | Screening method for an agent for suppressing the decrease in degradation of denatured elastin, an agent for maintaining normal elastin fibers, an agent for suppressing the formation of an elastin-elastin complex, and a method for examining a substance having an effect of suppressing the formation of an elastin-elastin complex. | |
EP1570837A1 (en) | Dendrite elongation inhibitor for melanocyte and skin preparation for external use containing the same | |
KR20190108425A (en) | Composition of skin external application for promoting skin volume or renewing | |
JP2018108973A (en) | Type xvii collagen production promoter | |
JP2022022672A (en) | Inflammatory cytokine inhibitor | |
CN101869573B (en) | Aqueous solution of silybin glucoside and external composition for skin | |
JP2022165426A (en) | Agent for promoting production of elastin | |
KR20190108427A (en) | Composition of skin external application for promoting skin volume or renewing | |
CN114209628A (en) | Plant extract composition with whitening effect and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |